<?xml version="1.0" encoding="UTF-8"?><CAS version="2"><uima.cas.Sofa _indexed="0" _id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="P09778197A0415 Cost-effectiveness analysis provides a rational means of allocating limited health care resources by allowing the comparison of the costs of lipid-lowering therapy, in particular, therapy with beta-hydroxy-beta-methylglutaryl-CoA (coenzyme A) reductase inhibitors (statins), with the costs of atherosclerosis that could be prevented by lowering cholesterol."/><uima.tcas.DocumentAnnotation _indexed="1" _id="8" _ref_sofa="1" begin="0" end="372" language="x-unspecified"/><edu.cmu.tanl.type.gene _indexed="1" _id="13" _ref_sofa="1" begin="167" end="222" Gene="beta-hydroxy-beta-methylglutaryl-CoA (coenzyme A) reductase"/></CAS>